A Wildean Portfolio: Relay Therapeutics’ 60% Surge and the Alchemy of Biotech Investment

The SEC filing of November 14 reveals a tale not merely of numbers, but of conviction masquerading as arithmetic. Commodore’s stake swelled to 17 million shares, valued at $88.7 million – a position now constituting 4.3% of their U.S. equity portfolio. One might say they’ve traded the Philosopher’s Stone for a pipette and a supercomputer, seeking not gold but genetic enlightenment.


